Elderly patients

Elderly patients

Subgroup analyses of LUX-Lung 3 and LUX-Lung 6 patients showed that afatinib* treatment resulted in significant progression-free survival (PFS) benefit versus chemotherapy in patients aged ≥65 years in the overall study populations (median PFS in LUX-Lung 3: 11.3 vs 8.2 months, hazard ratio [HR]=0.64; 95% confidence interval [CI]: 0.39–1.03; median PFS in LUX-Lung 6: 13.7 vs 4.1 months; HR=0.16; 95% CI: 0.07–0.39). Afatinib was also associated with PFS benefit in patients in this age group whose tumors had common epidermal growth factor receptor (EGFR) mutations (median PFS in LUX-Lung 3: 13.7 vs 8.2 months; HR=0.45; 95% CI: 0.26–0.78; median PFS in LUX-Lung 6: 13.7 vs 4.1 months; HR=0.15; 95% CI: 0.06–0.38).1 A significant increase in overall survival (OS) was also reported in elderly patients with del19 mutations in LUX-Lung 3 (median OS in this patient population: 41.5 vs 14.3 months; HR=0.39; 95% CI: 0.19–0.80).1 The safety profile of afatinib was generally similar across age groups, with a slightly higher incidence of Grade 3/4 treatment-related adverse events in elderly patients; however, this was also seen in the chemotherapy arm (cisplatin/pemetrexed in LUX-Lung 3 and cisplatin/gemcitabine in LUX-Lung 6).1

PFS in patients aged ≥65 years with common EGFR mutations (del19/L858R) in LUX-Lung 31

LUX-Lung 3: figure for PFS in elderly patients with afatinib vs cis/gem

CI, confidence interval; Cis, cisplatin; HR, hazard ratio; Pem, pemetrexed; PFS, progression-free survival.

PFS in patients aged ≥65 years with common EGFR mutations (del19/L858R) in LUX-Lung 61

LUX-Lung 6: figure for PFS in elderly patients with afatinib vs cis/pem

CI, confidence interval; Cis, cisplatin; Gem, gemcitabine; HR, hazard ratio; PFS, progression-free survival.

In exploratory analyses of LUX-Lung 7, there was a trend towards improved median PFS with afatinib versus gefitinib across all age groups analysed.1 OS with afatinib was generally consistent across age groups in LUX-Lung 7.1

OS by age group in LUX-Lung 71

LUX-Lung 7: forest plot for overall survival by age group with afatinib vs gefitinib

CI, confidence interval; HR, hazard ratio; OS, overall survival.

Did you find this information useful?

References

1

Wu YL, et al.  Clin Lung Cancer 2018;19(4):e465–79.

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: January 2021